Decision AI · Strategy, Analytics and AI Teams
Decision Infrastructure grounded in causality, context, and memory, so every decision gets faster, sharper, and smarter than the last.
Book a Demo
.avif)

.avif)
.avif)
.avif)
.avif)
.avif)
.avif)



.avif)
.avif)
.avif)
.avif)
Trusted by Strategy & AI Teams
Real World Decisions with Consequence
Move spend, inventory, and teams toward growth. For commercial teams that need to explain gaps, reallocate capital, and act before the quarter is gone, across CPG and Pharma.
3 SKU-region pairs show sell-in/sell-out diverging 8%+; 187 lines below confidence threshold
Reconcile ₹340 Cr into one trusted number, then commit the order at 94% confidence.
Region 3 decline traced to distribution, not demand
Cut the 12 SKUs running margin-negative for 3 consecutive quarters.
8 SKUs in Modern Trade cross the elasticity threshold
Reprice those 8 SKUs as elasticity crosses the margin floor.
Shelf capacity is the binding constraint in 2 depots
Hold current assortment in 2 depots rather than force a change shelf space can't support.
Elasticity now favors a 60:40 Modern Trade / CSD mix
Reallocate ₹8 Cr to South & East for 2.3x incremental margin.
40 HCPs show flat engagement this cycle
Prioritise 3 HCPs today at 3.2x uplift over list average.
Competitor spend drops ahead of Q4
Move ₹16 Cr from TV to digital for 1.8x ROAS uplift.
Prevent quality, yield, and downtime losses before they surface. For operations and quality teams that need to trace risk across inputs, process, equipment, and outcomes.
6-hour changeover on next week's run threatens ship date
Resequence the run to absorb the changeover without missing the ship date.
Station 4 is the recurring constraint across the last 3 shifts
Rebalance 2 stations on Line 3 before the shift-end bottleneck repeats.
Line 3 deviation crosses the quality floor
Halt Batch 512 in-process and escalate for regulatory notification.
Line 1 bearing wear pattern signals failure risk 48 hrs out
Schedule preventive maintenance on Line 1 before the next unplanned stop.
Process parameter P4 traced to input variance
Change process parameter P4 and flag Supplier 2's CoA drifting from baseline.
Supplier 4's landed cost rises for a third cycle of elevated risk
Hold in-house production as the buy option's landed cost is now higher.
Find the signal, choose the bet, and move faster. For scientific, medical, and innovation teams where each decision carries regulatory, portfolio, or time-to-market risk.
Candidate C's ADMET risk outweighs its potency gain
Rank 3 lead candidates against portfolio budget before advancing one to preclinical.
Compound Z's tox read shows an unresolved finding (Finding 4)
Clear Compound Y's IND-enabling tox go/no-go ahead of the filing window.
Lock the 6-week visit schedule. 8 weeks lifts dropout 34%
Open sites in Germany & Poland, enrolling 23% faster.
Module 3 carries the dossier's highest amendment risk
Sequence the EU filing ahead of the US as EMA review risk is lower this cycle.
Drug X safety signal crosses the WHO-UMC threshold
Escalate ICSR Case 4471 with the 15-day deadline at risk.
Programme Y's cost now exceeds expected value
Advance Compound X to Phase 3 with thresholds met; drop Programme Y.
Every stage has a window. The shelf doesn't wait for the next one. For CPG innovation and brand teams making launch decisions against a fixed retail calendar, not a lab deadline.
Concept F's margin potential falls below the portfolio floor
Fund 2 of 9 flavor concepts as the only pair clearing category-fit and margin thresholds.
North region is distribution-constrained ahead of launch
Commit launch volume at 40K units as shelf capacity caps upside in 2 regions.
The "natural" claim is pending one more lab verification cycle
Lock the reduced-sugar claim as the compliance review clears with no amendment.
Depot 3 sits 9 days behind the shelf-ready commitment
Confirm the March scale-up date as supply and shelf timing now align.
Elasticity held steady through the miss — price ruled out as a cause
Trace the flavor SKU's forecast miss to distribution, not demand, in 2 regions.
Neither reformulate nor relaunch-as-is clears the margin floor alone
Reformulate over re-launch as-is; margin impact favours reformulation by 1.6x.
The Platform
DecisionX connects your data, domain knowledge, and decision history into a living causal model, then reasons through it to give you a decision, not just an answer.

Every decision runs on four capabilities working together - from live signal to board-ready narrative.
Internal systems and external market data, fused into one continuously updating context.
Explore Signals
Root-cause analysis and forecasting grounded in cause and effect, not correlation.
Explore Reasoning
Every decision captured in one place, tracked over time, and compounding into institutional memory.
Explore Boards
Board-ready analysis and narratives generated on demand, sourced straight from live decisions.
Explore ReportsThe Architecture
DecisionX autonomously constructs a living Decision Ontology by connecting your Data, Domain, and Process ontologies into a single Causal State Graph.
A living model that continuously learns what decisions matter, what drives them, and why, across your entire enterprise.
The Value
Impact that shows up on the P&L, in revenue, in cost, and in how the organisation itself is built to decide.
Not demos. Not projections. Revenue and growth outcomes running in CPG and Pharma enterprises today.
Pharma · R&D
Global Pharma Conglomerate
90%
faster AE triage
100%
of 15-day regulatory deadlines met
3×
more signals caught early
Millions of adverse event reports annually. Manual triage, missed signals, 15-day regulatory deadline pressure on every serious case.
Manufacturing · Quality
Leading Textile Manufacturer
60%
of quality defects prevented
48h
predictive alert window
100%
raw-material-to-defect traceability
Quality failures traced to raw material variance, caught too late, post-production. No causal chain from input to defect.
Pharma OTC · Commercial
Global Pharma OTC Business
35%
marketing efficiency gain
2×
sales rep productivity
3wk
faster campaign decisions
Marketing spend without channel-level ROI visibility. Campaign decisions on lag data. Sales teams unable to prioritise at scale.
One ontology, built once in hours, then every downstream gain compounds into cost savings and operating efficiency.
Without DecisionX
With DecisionX
The shift
6–8 months manual ontology build
Setup cost saved
From months to hours. Manual work done autonomously.
Hallucinating generic AI
Risk cost avoided
Grounded in your context. Every inference anchored to your data, not generic world knowledge.
20-day analyst sprint
Analyst time saved
Decision workflows, not projects. 20-day analyst sprints, now a 30-second workflow.
High analyst dependency
Headcount savings
Fewer bottlenecks, faster board prep. Analyst dependency and coordination overhead, eliminated.
Value that doesn't show up as a single line item. It changes what kind of organisation you are.
Sovereignty
Your data. Your models. Your infrastructure.
AI-Native Organisation
Agents embedded in how decisions get made, not bolted onto how they used to.
Decision Quality
Fewer decisions made on stale data or gut instinct.
Industries
DecisionX is specific enough for regulated, operational, and commercial contexts where a plausible answer is not enough. Each area below runs its own full decision lifecycle in depth on its own page, this is the summary.
High-cost decision types
A trial signal, a batch disposition, and a launch call are the same decision chain, not three separate reviews. DecisionX connects R&D, Manufacturing, and Commercial into one traceable story.
How one decision moves through all three functions
Adjudicates the trial signal against protocol and prior evidence.
Trial 3 shows an unexpected interaction with a common comorbidity medication.
Adjudicates batch disposition under audit-ready evidence.
The affected lot is flagged for expanded stability testing before release.
Ranks the HCP call list before launch messaging goes out.
HCP outreach is held on the affected indication while the stability read is pending.
High-cost decision types
A demand signal, a changeover decision, and a launch call are the same decision chain, not three separate meetings. DecisionX connects NPD, Manufacturing, and Commercial for CPG and FMCG brands into one traceable story.
How one decision moves through all three functions
Diagnoses why a launched SKU is under- or over-performing forecast.
A flavor SKU misses its launch forecast in two regions.
Attributes yield loss to the process step where it occurs.
The same SKU's changeover loss is flagged as the line's top waste driver.
Allocates the trade budget by incremental return, not history.
Reformulation is funded from the trade budget the changeover fix freed up.
High-cost decision types
A supplier delay, a line-capacity call, and a customer delivery commitment are the same decision chain, not three separate escalations. DecisionX connects Supply Chain, Plant Operations, and Order Fulfillment into one traceable story, across any manufacturing vertical.
How one decision moves through all three functions
Extends, holds, or unwinds a hedge position against live commodity exposure.
A key raw-material supplier flags an 11-day delay while the same commodity trends 8% up on the exchange.
Decides make vs. buy inside a booking window that closes fast.
The affected line reprioritizes its schedule and evaluates a make-vs-buy call before the delay hits the floor.
Protects or renegotiates a delivery commitment before the ship date is missed.
The customer delivery commitment is protected with alternate sourcing or a renegotiated date.
Enterprise Trust
Every answer traces to source, logic, assumptions and the full reasoning chain.
Ontology Agents build the model. Your team reviews, edits and governs before it reasons.
SOC 2 Type II, GDPR, ISO 27001. Public and private cloud. RBAC, IAM, SSO.
Every tracked decision sharpens the ontology. Institutional intelligence that grows with use.
Decision intelligence platform
See DecisionX on your data, your context, your decisions. First value in 15 days.